Patents Represented by Attorney Carol L. Bozicevic, Field & Francis LLP Francis
-
Patent number: 6127598Abstract: The present invention features mouse models for Nkx-2.2 gene function and for Nkx-6.1 gene function, wherein the transgenic mouse is characterized by having a defect in Nkx-2.2 gene function or a defect in Nkx-6.1 gene function (where, because Nkx-2.2 acts upstream of Nkx-6.1, a defect in Nkx-2.2 gene function affects Nkx-6.1 gene function) and by having a decreased number of insulin-producing cells relative to a normal mouse. Where the transgenic mouse contains a defect in Nkx-2.2 gene function, the mouse is further characterized by a decreased number of serotonin-producing cells relative to a normal mouse. The transgenic mice may be either homozygous or heterozygous for the Nkx-2.2 or Nkx-6.1 defect.Type: GrantFiled: July 25, 1997Date of Patent: October 3, 2000Assignee: The Regents of the University of CaliforniaInventors: Michael S. German, John L.R. Rubenstein, Lori Sussel, Maike Sander, Dennis J. Hartigan-O'Connor, Roger A. Pedersen, Juanito J. Meneses
-
Patent number: 6123938Abstract: The present invention is based on the purification and sequencing of isozymes of plasma hyaluronidase (pHAse) found in urine. Specifically, urine contains two hyaluronidases (HAses): 1) a 57 kDa HAse that is apparently the same as the 57 kDa HAse found in plasma; and 2) a 45 kDa HAse, which is found in urine but not plasma. The smaller urine isozyme is composed of two disulfide-linked polypeptides produced by endoproteolytic cleavage of the 57 kDa isoform. The present invention thus features a urinary hyaluronidase (uHAse) polypeptide and nucleotide sequences encoding a Chain A polypeptide and a Chain B polypeptide, the two polypeptides of which uHAse is composed. In a particular aspect, the uHAse is a human uHAse (huHAse), preferably a huHAse composed of the Chain A and B polypeptides having SEQ ID NOS: 2 and 4, respectively. In related aspects the invention features polynucleotide sequence encoding Chain A and Chain B polypeptides, preferably having the sequences of SEQ ID NOS: 1 and 3, respectively.Type: GrantFiled: December 9, 1997Date of Patent: September 26, 2000Assignee: The Regents of the University of CaliforniaInventors: Robert Stern, Anthony Csoka, Gregory I. Frost, Tim M. Wong
-
Patent number: 6114114Abstract: A method and system for quantifying the relative abundance of gene transcripts in a biological sample. One embodiment of the method generates high-throughput sequence-specific analysis of multiple RNAs or their corresponding cDNAs (gene transcript imaging analysis). Another embodiment of the method produces a gene transcript imaging analysis by the use of high-throughput CDNA sequence analysis. In addition, the gene transcript imaging can be used to detect or diagnose a particular biological state, disease, or condition which is correlated to the relative abundance of gene transcripts in a given cell or population of cells. The invention provides a method for comparing the gene transcript image analysis from two or more different biological samples in order to distinguish between the two samples and identify one or more genes which are differentially expressed between the two samples.Type: GrantFiled: July 29, 1994Date of Patent: September 5, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jeffrey J. Seilhamer, Randal W. Scott
-
Patent number: 6046002Abstract: The invention features methods for identifying gene products that mediate a phenotype, such as drug resistance or sensitivity, as well as methods for identifying new bioactive compounds, by detecting differences in sensitivity of growth rate between host cells that differ in target gene product dosage (e.g., two copies of a target gene product-encoding sequence compared to one copy).Type: GrantFiled: January 5, 1998Date of Patent: April 4, 2000Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ron Davis, Guri N. Giaever, Dan Shoemaker
-
Patent number: 6017710Abstract: The invention features polynucleotides encoding novel GTP-binding polypeptides, hereinafter referred to as RAQ polypeptides; expression vectors comprising a RAQ polynucleotide of the invention; isolated cells comprising a RAQ-encoding vector; a transgenic non-human animal comprising an alteration in a RAQ gene; and the use of RAQ polynucleotides in detecting in an individual the presence of a genetic polymorphism of a RAQ gene. The invention further features novel RAQ polypeptides; monoclonal antibodies specific for RAQ polypeptides; and a method for making RAQ polypeptides.Type: GrantFiled: May 13, 1998Date of Patent: January 25, 2000Assignee: AxyS Pharmaceuticals, Inc.Inventors: Maxine J. Allen, Marc Rutter, Alan J. Buckler
-
Patent number: 6014969Abstract: A disposable package, tape, and cassette are provided which makes it possible to hold and disperse therefrom liquid, flowable formulations including aqueous formulations (solutions or dispersions with particles less than 0.25 microns in diameter) of a pharmaceutically active drug. In one embodiment formulation is packaged in individual dosage unit containers which containers are preferably interconnected. The package is designed to be integrated into a cassette which can be loaded into a dispersing device capable of individually opening dosage unit containers and aerosolizing the contents through a porous membrane, into a mouth piece on the cassette, for delivery to a patient. In addition to and alongside of each porous membrane, the package may include one or more openings through which air is forced in order to aid in avoiding the accumulation of aerosolized particles.Type: GrantFiled: October 26, 1998Date of Patent: January 18, 2000Assignee: Aradigm CorporationInventors: Lester John Lloyd, Peter M. Lloyd, Reid M. Rubsamen, Jeffrey Arthur Schuster
-
Patent number: 6004944Abstract: Secretory gland cells, particularly pancreatic, hepatic, and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the bloodstream to obtain therapeutic levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term or short term therapies for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: GrantFiled: October 2, 1997Date of Patent: December 21, 1999Assignee: The Regents of the University of CaliforniaInventors: Stephen S. Rothman, Ira D. Goldfine, Michael S. German
-
Patent number: 5985615Abstract: Switch regions derived from an immunoglobulin (Ig) gene are used to direct recombination between a targeting construct containing a promoter, a switch region (S.sub.1), and 2) a target locus minimally containing a promoter, a switch region (S.sub.2), and a target sequence.Type: GrantFiled: June 17, 1997Date of Patent: November 16, 1999Assignees: Abgenix, Inc., Japan Tobacco Inc.Inventors: Aya Jakobovits, Michael Lajos Gallo, Xiao-Ping Yang
-
Patent number: 5968981Abstract: A method of suppressing ventricular muscle cell hypertrophy induced by an .alpha..sub.1 -adrenergic agonist or endothelin, by providing an effective amount of a retinoic acid compound. Also provided are methods for identifying compounds which suppress ventricular muscle cell hypertrophy, compounds which inhibit the retinoic acid suppression of ventricular muscle cell hypertrophy, and therapeutic methods.Type: GrantFiled: March 10, 1998Date of Patent: October 19, 1999Assignee: The Regents of the University of CaliforniaInventors: Kenneth R. Chien, Ming Dong Zhou
-
Patent number: 5916771Abstract: The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.Type: GrantFiled: October 11, 1996Date of Patent: June 29, 1999Assignees: Abgenix, Inc., Japan Tobacco Inc.Inventors: Nobuaki Hori, Claude Geoffrey Davis, Krisztina M. Zsebo, Aya Jakobovits